For Healthcare Professionals

Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant


About the study

Primary Objective: -To demonstrate the benefit of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone in the prolongation of progression free survival (PFS) as compared to bortezomib, lenalidomide, and dexamethasone, in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant. Secondary Objectives: To evaluate in both randomized (isatuximab, bortezomib, lenalidomide and dexamethasone combination (IVRd) and bortezomib, lenalidomide and dexamethasone combination (VRd)) arms: Complete response (CR) rate, as defined by the International Myeloma Working Group (IMWG) criteria. Minimal residual disease (MRD) negativity rate in patients with CR. Very good partial response or better rate, as defined by the IMWG criteria. Overall survival (OS). To evaluate the overall response rate (ORR) as per IMWG criteria. To evaluate the time to progression (TTP) overall and by MRD status. To evaluate PFS by MRD status. To evaluate the duration of response (DOR) overall and by MRD status. To evaluate time to first response (TT1R). To evaluate time to best response (TTBR). To evaluate progression-free survival on next line of therapy (PFS2). To evaluate the sustained MRD negativity >12 months rate. To evaluate safety. To determine the pharmacokinetic (PK) profile of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (IVRd arm only). To evaluate the immunogenicity of isatuximab in patients receiving isatuximab (IVRd and crossover arms). To assess disease-specific and generic health-related quality of life (HRQL), disease and treatment-related symptoms, health state utility, and health status.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

Inclusion criteria :

  1. Multiple myeloma (IMWG criteria).
  2. Newly diagnosed multiple myeloma not eligible for transplant due to age (≥ 65 years) or patients < 65 years with comorbidities impacting possibility of transplant.
  3. Evidence of measurable disease.
  4. Written informed consent.


Exclusion criteria:

  1. Age < 18 years.
  2. Prior treatment for multiple myeloma.
  3. Any other prior or ongoing disease/health conditions incompatible with the study objectives.
  4. Organ function values not met.
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status ( PS) > 2.
  6. Hypersensitivity to the study medications.
  7. Pregnant, breastfeeding, or woman of child bearing potential unwilling to use recommended contraception methods.
  8. Male participants who disagree to follow the study contraceptive counseling.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Plasma Cell Myeloma

Age (in years)

18 - 80


Phase 3

Participants needed


Est. Completion Date

Jun 30, 2027

Treatment type



Sanofi identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.